EUVIMEDEUVIMED entdecken
Crossref

EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective

Eleni Frangou, Annette Bruchfeld iD, Gema M Fernandez-Juarez, Jürgen Floege, Dimitrios Goumenos, Sarah M Moran iD, Stefanie Steiger, Kate I Stevens iD, Kultigin Turkmen, Andreas Kronbichler

Nephrology Dialysis Transplantation · 2024

DOI: 10.1093/ndt/gfad230 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2024. Verfasst von Eleni Frangou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Limassol General Hospital, Limassol, Cyprus; University of Nicosia Medical School, Nicosia, Cyprus. Hauptthemen laut MEDLINE: Lupus Nephritis, Nephrology, Societies, Medical. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: CSL Behring, Vifor Pharma, Otsuka Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the 2023 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of systemic lupus erythematosus (SLE), the task force make three specific suggestions for the management of lupus nephritis (LN) and place strong emphasis on the treatment of active LN [1]. This is primarily a consequence of the recent approvals of belimumab, a monoclonal antibody directed against the cytokine BLyS, and voclosporin, a novel calcineurin inhibitor, as add-on therapies for the management of active LN. This editorial specifically focuses on the key clinical trials (Belimumab International Study in Lupus Nephritis (BLISS-LN) [2] and Aurinia Renal Response in Active Lupus With Voclosporin (AURORA-1) [3]) that form the basis for the updated EULAR recommendations. In brief, belimumab and voclosporin were tested on top of standard-of-care therapy in the BLISS-LN and AURORA-1 trials (see Table 1 for details) [2, 3]. The endpoint measurements differed between the two trials (Table 1) but the primary endpoint was reached by 43% in the belimumab arm in BLISS-LN at 104 weeks (versus 32% in the placebo arm) and 41% in the voclosporin arm in AURORA-1 at 52 weeks (versus 23% in the placebo arm) [2, 3]. Observational studies demonstrated that phases of active LN, encountered in 24% of study visits, increase the likelihood of developing progressive kidney damage in over 50% of cases [4]. Failure to achieve at least a partial renal response at 12 weeks predicted not only a higher Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index, but also a higher cumulative glucocorticoid exposure over time [5]. To this end, the 2023 EULAR update of the recommendations state that the addition of either belimumab or voclosporin should be considered upfront [1], as the remission rates achieved in clinical trials in control arms were low, and achieving no remission was associated with damage accrual. Differences among the two key trials leading to approval of belimumab (BLISS-LN) and voclosporin (AURORA-1) in patients with active LN classes III–V. In the results section, the active group (belimumab or voclosporin) is always given first. aPrimary efficacy renal response (primary endpoint): UPCR of ≤0.7, eGFR no worse than 20% below the pre-flare value or at ≥60 mL/min/1.73 m2, and no use of rescue therapy for treatment failure. bBased on estimates given in Supplementary data, Fig. S4 of the original manuscript. cPrimary endpoint (complete renal response): UPCR of ≤0.5 mg/mg, eGFR of ≥60 mL/min/1.73 m2 and no confirmed eGFR decrease of more than 20% from baseline. AZA, azathioprine; CYC, cyclophosphamide; GC, glucocorticoid; MMF, mycophenolate mofetil; MP, methylprednisolone; SD, standard deviation; UPCR, urinary protein to creatinine. Differences among the two key trials leading to approval of belimumab (BLISS-LN) and voclosporin (AURORA-1) in patients with active LN classes III–V. In the results section, the active group (belimumab or voclosporin) is always given first. aPrimary efficacy renal response (primary endpoint): UPCR of ≤0.7, eGFR no worse than 20% below the pre-flare value or at ≥60 mL/min/1.73 m2, and no use of rescue therapy for treatment failure. bBased on estimates given in Supplementary data, Fig. S4 of the original manuscript. cPrimary endpoint (complete renal response): UPCR of ≤0.5 mg/mg, eGFR of ≥60 mL/min/1.73 m2 and no confirmed eGFR decrease of more than 20% from baseline. AZA, azathioprine; CYC, cyclophosphamide; GC, glucocorticoid; MMF, mycophenolate mofetil; MP, methylprednisolone; SD, standard deviation; UPCR, urinary protein to creatinine. Both belimumab and voclosporin are useful additions to the armamentarium to optimize LN management. However, which of these two agents should be the preferred treatment choice for patients with LN (see considerations by this group in Fig. 1)? The 2023 EULAR update outlines differences in trial designs. Patients with an estimated glomerular filtration rate (eGFR) of 60 mL/min/1.73 m2 and an average eGFR of 100.5 mL/min/1.73 m2; thus, information on patients with lower eGFR categories is also limited for belimumab [2]. Yet, logic dictates that those with active LN irrespective of eGFR should probably receive more ‘aggressive’ therapies, in an endeavour to prevent further decline in eGFR. Specific considerations when evaluating the optimal currently approved add-on therapy of a patient with active LN class III–V. BEL, belimumab; i.v., intravenous; s.c., subcutaneous; VCS, voclosporin. Long-term glucocorticoid exposure is common in patients with LN, either as part of the strategy to maintain remission in LN or to control extra-renal disease activity. Assuming there are no contraindications, patients should be commenced on intravenous methylprednisolone (250–1000 mg for 1–3 pulses) followed by a lower-dose glucocorticoid regimen (starting dose 0.3–0.5 mg/kg/day and 20 mg/day for classes III–V). This recommendation largely reflects the use of glucocorticoids in the AURORA-1 trial and the 2023 EULAR update acknowledges the lack of high-quality data for this statement [1]. Limited data are available in patients receiving belimumab, although a glucocorticoid-sparing effect was proposed. Although the 2023 EULAR update proposes that besides voclosporin, a second calcineurin inhibitor, tacrolimus, can be used equivalently to manage active LN [1], there is no evidence from high-quality clinical trials about tacrolimus efficacy outside of China [6]. The largest trial included a total of 368 LN patients with a follow-up of 6 months. Patients in both groups [intravenous cyclophosphamide versus low-dose tacrolimus (2 mg twice daily) plus low-dose MMF (500 mg twice daily)] received three doses of intravenous methylprednisolone (500 mg) upfront, followed by an oral glucocorticoid dose of 0.6 mg/kg per day for 4 weeks and a slow taper until 10 mg/day was reached. Thus, the total glucocorticoid exposure in the trial by Liu et al. [7] is not comparable to more contemporary approaches in reducing the use of glucocorticoids, as also stated by the 2023 EULAR update [1]. In the pivotal tacrolimus trial, an astonishing number of 213 participants (57.9%) did not complete the 24 weeks of the trial [7]. Importantly, the side-effect spectrum of voclosporin and other calcineurin inhibitors, such as tacrolimus, is different, with voclosporin having lower frequencies of nephrotoxicity, neurotoxicity, dyslipidemia and de novo diabetes mellitus [8]. Most of these estimates stem from kidney transplant recipients. It remains unclear whether these side effects are observed at the same frequency in patients with LN receiving tacrolimus. Nonetheless, the European Renal Association–Immunonephrology Working Group believes that, despite the potential cost reduction associated with tacrolimus compared with voclosporin, the recommendation for the use of tacrolimus is not currently supported by sufficient evidence, other than in a Chinese population (see theSupplementary data for a current price estimate of both agents). Tacrolimus might, however, be considered in countries where voclosporin will not become readily available (including in low-income countries). The ultimate goal of therapy is to prevent further episodes of active LN thus reducing the likelihood of progressive nephron loss. The 2023 EULAR update recommends that treatment for LN should be continued for at least 3 years [1]. The BLISS-LN trial followed patients for 104 weeks, while recently published results from the AURORA-2 trial evaluated 216 of the 357 patients that were originally randomized in the AURORA-1 trial for another 104 weeks. Briefly, AURORA-2 found that the improved proteinuria response persisted up to 3 years and, eventually led to more renal responses in patients receiving voclosporin. In AURORA-2, the corrected eGFR (all values higher >90 mL/min/1.73 m2 were constrained to 90 mL/min/1.73 m2) slope was –0.2 mL/min/1.73 m2 and –5.4 mL/min/1.73 m2 in the voclosporin and control groups, respectively [9]. This further demonstrates that nephrotoxicity over time seems to be only a minor issue for voclosporin. The 2023 EULAR update states that glucocorticoids should be withdrawn as soon as sustained remission is achieved. The 10-year follow-up data from the Euro-Lupus Nephritis Trial reported the ongoing use of glucocorticoids in 73% of patients and alternative immunosuppressants in 56% in spite of good clinical renal outcome [10]. Based on these real-life data of individuals receiving cyclophosphamide induction therapy, it seems relevant that glucocorticoids are tapered to the lowest possible dose early in the maintenance phase and ideally discontinued if extra-renal manifestations permit. The EULAR 2023 update recommends a maintenance dose of ≤5 mg/day [1]. Observational data indicated that glucocorticoid doses >5 mg are associated with damage accrual in patients with SLE [11]. However, large registries of other autoimmune disorders, such as rheumatoid arthritis, revealed that even lower doses (≥5 mg) and cumulative doses of >0.75 g over the preceding 6 months contribute to the risk of developing cardiovascular events [12], a finding likely also of relevance for patients with LN, who have a high burden of cardiovascular morbidity and mortality. The EULAR recommendations also note the potential value of repeated kidney biopsy to guide reduction and withdrawal of immunosuppression, when patients are in remission for at least 2 years [1]. In the case of limited/no evidence of histologic activity (National Institutes of Health Activity Index of ≤1), reducing or stopping glucocorticoids might be attempted if such agents are used to maintain remission. Other immunosuppressants might be reduced/withdrawn over time. Evidence for such an approach is promising, although this has not been confirmed in a randomized controlled trial setting. Combining histological and certain clinical parameters, e.g. degree of residual proteinuria, complement serology, antibody profile and adverse event occurrence or risk, might provide further insight to help guide withdrawal of immunosuppression after 3 years of continuous therapy. Although recent studies performed in LN patients have been critical of the suggested revisions, the 2023 update of the EULAR recommendations for the management of SLE is an important resource for physicians caring for patients with SLE and active LN. The future research agenda mandates a strong focus on how to guide immunosuppression withdrawal and particularly notes the role of repeated kidney biopsy. Moreover, background disease medication—e.g. steroid—has to be addressed in future trial design to avoid both polypharmacy and ‘dilution’ of positive effects of drugs under study [1]. A high-dose background therapy could have potentially led to the failure of rituximab therapy to achieve significant results in the LUNAR (Lupus Nephritis Assessment with Rituximab) trial with an efficacy difference of 11% compared with the control group [13]. The ambition to reduce effective background therapies to provide a positive signal seems to be a worrisome suggestion for future clinical trials. It should not be. Ideally, these newer therapies may provide similar or better efficacy estimates as currently approved therapies and should provide such efficacy (and safety) on a standard background therapy. The use of sodium-glucose cotransporter 2 inhibitors as nephroprotective treatment is mentioned in the 2023 EULAR update; however, while preliminary data seem to be promising in patients with LN, a clinical trial focusing on nephroprotection is not highlighted in the future research agenda [14]. The future for new drugs in the field of LN looks promising, and newer therapies such as anifrolumab, obinituzumab and complement inhibitors will further refine therapies and improve understanding disease pathogenesis in more detail. Additionally, the importance of biomarkers in detection of disease activity, response to therapy and the early detection of non-response should not be overlooked. The Immunonephrology Working Group is an official body of the ERA. This work received no funding. A.K. drafted the first version of the article. All authors significantly contributed to the content and reviewed the manuscript. A.B. received consultancy fees and honoraria from Amgen, AstraZeneca, Bayer, Fresenius and CSL Vifor. K.I.S. received consultancy fees from Bayer and Boehringer Ingelheim. A.K. received consultancy fees from CSL Vifor, Otsuka, GSK, Walden Biosciences, Catalyst Biosciences and Delta4; and received unrestricted research grants from CSL Vifor and Otsuka. G.M.F.-J. received consultancy fees from GSK and Otsuka. The remaining authors disclosed no conflicts of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisNephrologySocieties, MedicalHumansEuropePractice Guidelines as TopicDisease ManagementImmunosuppressive Agents

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Nephrology, Limassol General Hospital, Limassol, Cyprus; University of Nicosia Medical School, Nicosia, Cyprus.
  • Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
  • Department of Renal Medicine, Karolinska University Hospital and CLINTEC Karolinska Institutet, Stockholm, Sweden.
  • Department of Nephrology, Hospital Unversitatio La Paz, Madrid, Spain ; Instituto de Investigacion la Paz, IDIPaZ, Spain.
  • Division of Nephrology, RWTH Aachen University Hospital, Aachen, Germany.
  • Department of Nephrology and Renal Transplantation, Patras University Hospital, Patras, Greece.

ORCID-Profile: Annette Bruchfeld, Sarah M Moran, Kate I Stevens

Förderung

  • CSL Behring
  • Vifor Pharma
  • Otsuka Pharmaceutical

Zitieren

APA

Frangou, E., Bruchfeld, A., Fernandez-Juarez, G. M., Floege, J., Goumenos, D., Moran, S. M., Steiger, S., Stevens, K. I., Turkmen, K., & Kronbichler, A. (2024). EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad230

Vancouver

Frangou E, Bruchfeld A, Fernandez-Juarez GM, Floege J, Goumenos D, Moran SM, et al. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrology Dialysis Transplantation. 2024. doi:10.1093/ndt/gfad230

BibTeX
@article{Frangou2024,
  author = {Frangou, Eleni and Bruchfeld, Annette and Fernandez-Juarez, Gema M and Floege, Jürgen and Goumenos, Dimitrios and Moran, Sarah M and Steiger, Stefanie and Stevens, Kate I and Turkmen, Kultigin and Kronbichler, Andreas},
  title = {EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective},
  journal = {Nephrology Dialysis Transplantation},
  year = {2024},
  doi = {10.1093/ndt/gfad230}
}
Kostenlos starten →